Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Celularity (CELU) Shares Outstanding (Weighted Average) (2020 - 2025)

Celularity (CELU) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $25.6 million as the latest value for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 16.94% year-over-year to $25.6 million; the TTM value through Dec 2025 reached $25.6 million, up 16.94%, while the annual FY2025 figure was $25.6 million, 128.12% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $25.6 million in Q4 2025 for Celularity, up from $17.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $166.0 million in Q2 2023 and bottomed at $10.1 million in Q1 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $44.7 million, with a median of $21.7 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Weighted Average) soared 1127.04% in 2021 and then tumbled 93.43% in 2024.
  • Celularity's Shares Outstanding (Weighted Average) stood at $67.1 million in 2021, then crashed by 79.14% to $14.0 million in 2022, then increased by 27.32% to $17.8 million in 2023, then grew by 22.89% to $21.9 million in 2024, then increased by 16.94% to $25.6 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $25.6 million, $17.1 million, and $24.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.